Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
Cattral
M S
MS
Multi-Organ Transplantation Program, Toronto Hospital, University of Toronto, Ontario, Canada.
Hemming
A W
AW
Greig
P D
PD
Rowsell
C
C
Chari
R
R
Wright
E
E
Donat
D
D
Cole
E
E
Levy
G A
GA
D000284:Administration, Oral; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone